Research & Development (R&D)

As a highly innovative medical technology company, we annually invest a large percentage of our revenue in research and development – the foundation for remaining a driver of medical progress in the future. Every day, we are driven by the quest for knowledge and the urge to continuously redefine the boundaries of what is physically conceivable.

Investment in R&D

Carl Zeiss Meditec Group has the necessary resources to secure the Company’s future earnings strength with its research and development activities. Thus we also want to offer innovations in future that make leading technologies available for our customers, and thus improve treatment results for patients.

It is therefore our aim to expand its product portfolio and continuously improve products already on the market. The main priority shall be to increase the efficiency and effectiveness of diagnosis and treatment. The Company attaches great importance to the needs of its customers and continuously works closely with them.
In financial year 2014/15 research and development expenses increased by 12.2% to € 112.0 million (prior year: € 99.8 million). At the same time the R&D ratio remained almost the same as the prior year, at 10.8% (prior year: 11.0%).

Show more
close

Research and development at the Company mainly focuses on:

  • examining new technological concepts in terms of their clinical relevance and effectiveness,
  • the continuous development of the existing product portfolio,
  • the development of new products and product platforms based on the available basic technologies and
  • networking systems and equipment to increase the efficiency of diagnosis and treatment and to improve treatment results for patients

 

New Markets

We believe that there will be positive growth in particular in the rapidly developing economies (RDEs) Asia and Latin America. We plan to further strengthen our market presence and exploit the existing potential there in order to establish ourselves even more firmly in these markets.

Product requirements in RDEs such as India or China are often very different to the requirements in established markets. That is why it is important to establish a market-specific product range. The Company has taken this step for the first time with the introduction of the phaco device Visalis® 100. This device was specially adapted to the requirements of the RDEs and has become very well established in the market there.

The goal of the Carl Zeiss Meditec AG is to make effective workflows for physicians possible. On fast-growing markets, where the number of patients is particularly high, a good usability, universal applicability and the cost factor play an important role.

ZEISS has expanded its OCT portfolio to include a compact solution with the launch of the PRIMUS 200. This is an easy-to-operate, versatile device that offers new possibilities in clinical care, particularly to physicians in smaller eye care practices and in countries with fast-growing markets. The OCT method makes it possible, for example, to visualize the retina in the posterior segment of the eye.

The OPMI LUMERA® 300 from ZEISS brings the advantages of the OPMI LUMERA series to the routine segment. The device offers an excellent price/performance ratio and provides best in glass visualization. In ophthalmic surgery, physicians benefit from the renowned quality of optics and illumination of the OPMI LUMERA product range.

However, we are also aware that meeting customer needs demands a stronger on-site presence. With the application and research centre “CARIn” (Center of Application and Research in India) targeted investments are being made in research and development projects in the immediate vicinity of our customers. Carl Zeiss Meditec’s AG strong distribution and service network serves at the same time to further develop its presence.

Show more
close
We use cookies on this site. Cookies are small text files that are stored on your computer by websites. Cookies are widely used and help to optimize the pages that you view. By using this site, you agree to their use. more